Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation.

NCT01895127 is registered in ClinicalTrials.gov with Brigham and Women's Hospital as lead sponsor.

NCT NCT01895127
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01895127 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation.
Lead sponsor
Brigham and Women's Hospital
Phase
Phase 2
Overall status
Terminated
Start date
November 30, 2013
Completion date
April 30, 2016
Enrollment
11 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

antibody-mediated rejection, humoral rejection